<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02710383</url>
  </required_header>
  <id_info>
    <org_study_id>BCF 06-2018</org_study_id>
    <nct_id>NCT02710383</nct_id>
  </id_info>
  <brief_title>Biomarker for Cystic Fibrosis</brief_title>
  <acronym>BioCyFi</acronym>
  <official_title>Biomarker for Cystic Fibrosis: An International, Multicenter, Observational, Longitudinal Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centogene AG Rostock</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centogene AG Rostock</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      International, multicenter, observational, longitudinal study to identify biomarker/s for
      Cystic fibrosis and to explore the clinical robustness, specificity, and long-term
      variability of these biomarker/s
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cystic fibrosis (CyFi) is a progressive hereditary disease with the prevalence of 1 in 2500.
      CyFi is an autosomal recessive disease caused by pathogenic variant/s in the CFTR (Cystic
      Fibrosis Transmembrane Conductance Regulator) gene encoding Cftr protein.

      CyFi causes chronic respiratory damage. Pulmonary findings occur already in infancy, which
      raises questions whether obstruction might be congenital. Thick, sticky mucus clogs the
      airways, reduces muco-ciliary clearance and leads to problems with breathing and recurrent
      bacterial (Pseudomonas aeruginosa) infections, which causes over time the formation of scar
      tissue (fibrosis) and cysts in the lungs.There is no cure for CyFi; however, symptomatic
      treatment can help relieve symptoms.

      The aim of this study is to identify biomarkers for Cystic fibrosis disease and to explore
      their clinical robustness, specificity, and long-term variability. An ideal biomarker plays
      an essential role in the early diagnosis, prediction and therapeutic monitoring of a specific
      disorder.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of Cystic fibrosis biomarker/s</measure>
    <time_frame>36 months</time_frame>
    <description>All samples will be analyzed for the identification of biomarker/s via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exploring the clinical robustness, specificity, and long-term variability of Cystic fibrosis biomarker/s</measure>
    <time_frame>36 months</time_frame>
    <description>Samples will be analyzed for the identified biomarker candidates via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Chronic Nasal Congestion</condition>
  <condition>Lung Infection</condition>
  <condition>Breathlessness</condition>
  <condition>Clubbing Toes</condition>
  <condition>Meconium Ileus</condition>
  <condition>Failure to Thrive</condition>
  <condition>Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Participants genetically diagnosed with Cystic fibrosis</arm_group_label>
    <description>Participants diagnosed with Cystic fibrosis aged between 2 months and 50 years</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample applied on the Dry Blood Spot (DBS) Filtercard (CentocardÂ®)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants genetically diagnosed with Cystic fibrosis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Informed consent is obtained from the participant or the parent/ legal guardian

          -  The participant is aged between 2 months and 50 years

          -  The diagnosis of Cystic fibrosis is genetically confirmed by CENTOGENE

        EXCLUSION CRITERIA:

          -  Informed consent is not obtained from the participant or from the parent/ legal
             guardian

          -  The participant is younger than 2 months or older than 50 years

          -  The diagnosis of Cystic fibrosis is not genetically confirmed by CENTOGENE
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arndt Rolfs, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centogene AG Rostock</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Volha Skrahina, PhD</last_name>
    <phone>+49 (0)38180113594</phone>
    <email>Volha.Skrahina@centogene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Amrita Institute of Medical Sciences &amp; Research Centre</name>
      <address>
        <city>Cochin</city>
        <state>Kerala</state>
        <zip>682041</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheela Nampoothiri, MD</last_name>
      <phone>+91 (0)4842851234</phone>
      <email>sheelanampoothiri@aims.amrita.edu</email>
    </contact>
    <investigator>
      <last_name>Sheela Nampoothiri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Navi Mumbai Institute of Research In Mental And Neurological Handicap (NIRMAN)</name>
      <address>
        <city>Mumbai</city>
        <zip>400705</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anil Jalan, MD</last_name>
      <phone>91 (0)2267910237</phone>
      <email>jalananil12@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Anil Jalan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lady Ridgeway Hospital for Children</name>
      <address>
        <city>Colombo 8</city>
        <zip>00800c</zip>
        <country>Sri Lanka</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eresha Jasinge, MD</last_name>
      <phone>+94 (0)112693711</phone>
      <email>eresha.jasinge@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Eresha Jasinge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
    <country>Sri Lanka</country>
  </location_countries>
  <removed_countries>
    <country>Egypt</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Pakistan</country>
    <country>Romania</country>
  </removed_countries>
  <link>
    <url>http://centogene.com</url>
    <description>CENTOGENE is a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for patients</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 11, 2016</study_first_submitted>
  <study_first_submitted_qc>March 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2016</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Meconium Ileus</mesh_term>
    <mesh_term>Dyspnea</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Failure to Thrive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

